![Rajesh Chopra](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Rajesh Chopra
Chief Executive Officer at Aethon Therapeutics, Inc.
Profile
Dr. Rajesh Chopra is a Venture Partner at Apple Tree venture Managemnet Llc//vc and a Chief Executive Officer & Director at Aethon Therapeutics, Inc. He is on the Board of Directors at Artios Pharma Ltd., Aethon Therapeutics, Inc. and Nereid Therapeutics, Inc. Dr. Chopra was previously employed as an Independent Non-Executive Director by e-Therapeutics Plc, a VP-Translational & Early Drug Development by Celgene Corp., a Director-Medical Science by AstraZeneca PLC, and a Director-Hematological Oncology Department by The Christie NHS Foundation Trust.
He received his undergraduate degree from the University College London, an undergraduate degree from The UCL Academy and a doctorate degree from the University College London.
Rajesh Chopra active positions
Companies | Position | Start |
---|---|---|
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Director/Board Member | 2019-02-10 |
Apple Tree venture Managemnet Llc//vc
![]() Apple Tree venture Managemnet Llc//vc Investment ManagersFinance Apple Tree venture Managemnet LLC (Apple Tree Partners) is a venture capital firm founded by Seth Harrison in 1999. The firm is headquartered in New York with an additional offices in London, San Francisco and Cambridge. | Private Equity Investor | 2020-03-31 |
Nereid Therapeutics, Inc.
![]() Nereid Therapeutics, Inc. BiotechnologyHealth Technology Nereid Therapeutics, Inc. operates as a life sciences venture firm. It translates the potential of biomolecular condensates into life-changing therapeutics. The company was founded by Clifford Brangwynne and Spiros Liras and is headquartered in Cambridge, MA. | Director/Board Member | - |
Aethon Therapeutics, Inc.
![]() Aethon Therapeutics, Inc. Hospital/Nursing ManagementHealth Services The company, co-founded by venture capital firm Apple Tree Partners and New York University cancer researchers Shohei Koide, Ph.D., and Benjamin G. Neel, Ph.D., unites immunotherapy and targeted therapy to expand the power and promise of both approaches for people living with cancer. Aethon Therapeutics, Inc. is based in New York, NY. Part of NYU Langone Medical Center, Aethon Therapeutics, Inc. is a company that creates neoantigens by design to transform cancer treatments into cures. The company's novel anti-drug-peptide conjugate/mhc antibodies are designed to be used in combination with targeted covalent inhibitors of ras, egfr, and other oncogenic driver mutations to mount immune attacks and selectively kill residual cancer cells, including drug-resistant "persister" cells. The company was founded by Benjamin G. Neel, Shohei Koide. The CEO is Rajesh Chopra. | Chief Executive Officer | - |
Former positions of Rajesh Chopra
Companies | Position | End |
---|---|---|
CELGENE | Corporate Officer/Principal | 2015-12-31 |
E-THERAPEUTICS PLC | Director/Board Member | 2015-10-28 |
ASTRAZENECA PLC | Corporate Officer/Principal | 2009-03-31 |
The Christie NHS Foundation Trust | Corporate Officer/Principal | - |
Training of Rajesh Chopra
University College London | Doctorate Degree |
The UCL Academy | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
E-THERAPEUTICS PLC | Health Technology |
ASTRAZENECA PLC | Health Technology |
Private companies | 6 |
---|---|
Celgene Corp.
![]() Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
The Christie NHS Foundation Trust | Miscellaneous |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Apple Tree venture Managemnet Llc//vc
![]() Apple Tree venture Managemnet Llc//vc Investment ManagersFinance Apple Tree venture Managemnet LLC (Apple Tree Partners) is a venture capital firm founded by Seth Harrison in 1999. The firm is headquartered in New York with an additional offices in London, San Francisco and Cambridge. | Finance |
Nereid Therapeutics, Inc.
![]() Nereid Therapeutics, Inc. BiotechnologyHealth Technology Nereid Therapeutics, Inc. operates as a life sciences venture firm. It translates the potential of biomolecular condensates into life-changing therapeutics. The company was founded by Clifford Brangwynne and Spiros Liras and is headquartered in Cambridge, MA. | Health Technology |
Aethon Therapeutics, Inc.
![]() Aethon Therapeutics, Inc. Hospital/Nursing ManagementHealth Services The company, co-founded by venture capital firm Apple Tree Partners and New York University cancer researchers Shohei Koide, Ph.D., and Benjamin G. Neel, Ph.D., unites immunotherapy and targeted therapy to expand the power and promise of both approaches for people living with cancer. Aethon Therapeutics, Inc. is based in New York, NY. Part of NYU Langone Medical Center, Aethon Therapeutics, Inc. is a company that creates neoantigens by design to transform cancer treatments into cures. The company's novel anti-drug-peptide conjugate/mhc antibodies are designed to be used in combination with targeted covalent inhibitors of ras, egfr, and other oncogenic driver mutations to mount immune attacks and selectively kill residual cancer cells, including drug-resistant "persister" cells. The company was founded by Benjamin G. Neel, Shohei Koide. The CEO is Rajesh Chopra. | Health Services |
- Stock Market
- Insiders
- Rajesh Chopra